Ptc Therapeutics (PTCT) EBIT (2012 - 2026)

Ptc Therapeutics' EBIT history runs 15 years deep, the most recent figure standing at $45.0 million for Q1 2026.

• On a quarterly basis, EBIT fell 95.37% year-over-year to $45.0 million in Q1 2026; TTM through Mar 2026 was -$58.3 million, a 108.18% decrease from a year earlier, with the FY2025 full-year figure at $866.9 million, up 386.52% from the prior year.
• EBIT grew to $45.0 million in Q1 2026 per PTCT's latest filing, from -$71.3 million in the prior quarter.
• Across five years, EBIT topped out at $970.2 million in Q1 2025 and bottomed at -$209.5 million in Q2 2023.
• The 5-year median for EBIT is -$68.2 million (2022), against an average of -$16.3 million.
• Across the five-year window, EBIT plunged 2890.19% in 2024 and soared 2234.57% in 2025, its largest moves.
• Year by year, EBIT stood at -$200.3 million in 2022, then jumped by 102.91% to $5.8 million in 2023, then plunged by 2890.19% to -$162.4 million in 2024, then surged by 56.06% to -$71.3 million in 2025, then soared by 163.01% to $45.0 million in 2026.
• Per Business Quant, the three latest PTCT EBIT figures stand at $45.0 million (Q1 2026), -$71.3 million (Q4 2025), and $3.0 million (Q3 2025).